A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19

The global Coronavirus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to unprecedented social and economic consequences. The risk of morbidity and mortality due to COVID-19 increases dramatically in the presence of co-existing medical conditions while the underlying mechanisms remain unclear. Furthermore, there are no proven effective therapies for COVID-19. This study aims to identify SARS-CoV-2 pathogenesis, diseases manifestations, and COVID-19 therapies using network medicine methodologies along with clinical and multi-omics observations. We incorporate SARS-CoV-2 virus-host protein-protein interactions, transcriptomics, and proteomics into the human interactome. Network proximity measure revealed underlying pathogenesis for broad COVID-19-associated manifestations. Multi-modal analyses of single-cell RNA-sequencing data showed that co-expression of ACE2 and TMPRSS2 was elevated in absorptive enterocytes from the inflamed ileal tissues of Crohn's disease patients compared to uninflamed tissues, revealing shared pathobiology by COVID-19 and inflammatory bowel disease. Integrative analyses of metabolomics and transcriptomics (bulk and single-cell) data from asthma patients indicated that COVID-19 shared intermediate inflammatory endophenotypes with asthma (including IRAK3 and ADRB2). To prioritize potential treatment, we combined network-based prediction and propensity score (PS) matching observational study of 18,118 patients from a COVID-19 registry. We identified that melatonin (odds ratio (OR) = 0.36, 95% confidence interval (CI) 0.22-0.59) was associated with 64% reduced likelihood of a positive laboratory test result for SARS-CoV-2. Using PS-matching user active comparator design, melatonin was associated with 54% reduced likelihood of SARS-CoV-2 positive test result compared to angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (OR = 0.46, 95% CI 0.24-0.86).

[1]  A. Barabasi,et al.  Network medicine framework for identifying drug-repurposing opportunities for COVID-19 , 2021, Proceedings of the National Academy of Sciences.

[2]  S. Ciesek,et al.  Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.

[3]  Victor G. Puelles,et al.  Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.

[4]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[5]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[6]  Catherine Klersy,et al.  Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy , 2020, The New England journal of medicine.

[7]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[8]  M. Hoffmann,et al.  A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells , 2020, Molecular Cell.

[9]  Hans Clevers,et al.  SARS-CoV-2 productively infects human gut enterocytes , 2020, Science.

[10]  Fabian J Theis,et al.  SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.

[11]  A. Barabasi,et al.  Network medicine framework for identifying drug-repurposing opportunities for COVID-19 , 2020, Proceedings of the National Academy of Sciences.

[12]  Jinlyu Sun,et al.  Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19 , 2020, Journal of Autoimmunity.

[13]  Daniel C. Baumgart,et al.  Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management , 2020, Clinical Gastroenterology and Hepatology.

[14]  Roland Eils,et al.  SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells , 2020, The EMBO journal.

[15]  Huji Xu,et al.  Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process , 2020, Gut.

[16]  Ying Zhu,et al.  O-GlcNAc transferase promotes influenza A virus–induced cytokine storm by targeting interferon regulatory factor–5 , 2020, Science Advances.

[17]  C. Whittaker,et al.  Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.

[18]  T. West,et al.  Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.

[19]  R. Albrecht,et al.  SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems , 2020, bioRxiv.

[20]  David Shum,et al.  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.

[21]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[22]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues , 2020, SSRN Electronic Journal.

[23]  F. Cheng,et al.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.

[24]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[25]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[26]  R. Nussinov,et al.  Computational network biology: Data, models, and applications , 2020 .

[27]  H. Shan,et al.  Evidence for Gastrointestinal Infection of SARS-CoV-2 , 2020, Gastroenterology.

[28]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[29]  Ruth Nussinov,et al.  Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes , 2020, PLoS Comput. Biol..

[30]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[31]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[32]  D. Burkhoff,et al.  Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease , 2020 .

[33]  Hao Zhou,et al.  Melatonin attenuates ER stress and mitochondrial damage in septic cardiomyopathy: A new mechanism involving BAP31 upregulation and MAPK‐ERK pathway , 2020, Journal of cellular physiology.

[34]  R. Zeng,et al.  Melatonin alleviates cigarette smoke-induced endothelial cell pyroptosis through inhibiting ROS/NLRP3 axis. , 2019, Biochemical and biophysical research communications.

[35]  Thomas L. Madden,et al.  Database resources of the National Center for Biotechnology Information. , 2019, Nucleic acids research.

[36]  S. Moon,et al.  Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions , 2019, BMC Infectious Diseases.

[37]  M. Vidal,et al.  A genome-wide positioning systems network algorithm for in silico drug repurposing , 2019, Nature Communications.

[38]  A. Mes-Masson,et al.  Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion , 2019, Nature Communications.

[39]  F. Cheng,et al.  Conformational Dynamics and Allosteric Regulation Landscapes of Germline PTEN Mutations Associated with Autism Compared to Those Associated with Cancer. , 2019, American journal of human genetics.

[40]  Albert-László Barabási,et al.  Network-based prediction of drug combinations , 2019, Nature Communications.

[41]  Xianyi Lian,et al.  Understanding Human-Virus Protein-Protein Interactions Using a Human Protein Complex-Based Analysis Framework , 2019, mSystems.

[42]  Judy H. Cho,et al.  Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy , 2019, Cell.

[43]  Feixiong Cheng,et al.  In Silico Oncology Drug Repositioning and Polypharmacology. , 2018, Methods in molecular biology.

[44]  W. Busse,et al.  BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and In fl uences of Medications , 2019 .

[45]  T. Scialla,et al.  L-Citrulline increases nitric oxide and improves control in obese asthmatics , 2019 .

[46]  Albert-László Barabási,et al.  Network-based approach to prediction and population-based validation of in silico drug repurposing , 2018, Nature Communications.

[47]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[48]  Jiro Wada,et al.  MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells , 2018, PloS one.

[49]  Evan Bolton,et al.  Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..

[50]  Sheng-Yong Yang,et al.  Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era , 2016, Briefings Bioinform..

[51]  S. Mulugeta,et al.  The biology of the ABCA3 lipid transporter in lung health and disease , 2016, Cell and Tissue Research.

[52]  F. Cheng,et al.  Drug Repurposing: New Treatments for Zika Virus Infection? , 2016, Trends in molecular medicine.

[53]  C. Mulder,et al.  Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease , 2016, Therapeutic drug monitoring.

[54]  V. Kutala,et al.  Association of serum interleukin-6, interleukin-8, and Acute Physiology and Chronic Health Evaluation II score with clinical outcome in patients with acute respiratory distress syndrome , 2016, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[55]  Zhongming Zhao,et al.  Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis , 2016, PLoS Comput. Biol..

[56]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[57]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[58]  H. Shimokawa,et al.  RhoA/Rho-Kinase in the Cardiovascular System. , 2016, Circulation research.

[59]  Feng Xu,et al.  Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..

[60]  Tieying Hou,et al.  Accuracy of serum interleukin (IL)-6 in sepsis diagnosis: a systematic review and meta-analysis. , 2015, International journal of clinical and experimental medicine.

[61]  Nan-nan Liu,et al.  Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity. , 2015, Antiviral research.

[62]  J. McDunn,et al.  Metabolomic Endotype of Asthma , 2015, The Journal of Immunology.

[63]  Ziv Bar-Joseph,et al.  Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. , 2014, American journal of respiratory and critical care medicine.

[64]  Zhongming Zhao,et al.  Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. , 2014, Molecular biology and evolution.

[65]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[66]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[67]  J. Ribeiro,et al.  Asthma: Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors , 2014, Allergy, Asthma & Clinical Immunology.

[68]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands , 2013, Nucleic Acids Res..

[69]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[70]  Kathryn L. Schornberg,et al.  FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection , 2013, Science Translational Medicine.

[71]  B. Korelitz.  Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. , 2013, World journal of gastroenterology.

[72]  Lisa E. Gralinski,et al.  Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus , 2013, mBio.

[73]  Judy H. Cho,et al.  Extended haplotype association study in Crohn’s disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-κB pathway gene, HEATR3 , 2013, Genes and Immunity.

[74]  M. Chan-yeung,et al.  Functional Genetic Variation in NFKBIA and Susceptibility to Childhood Asthma, Bronchiolitis, and Bronchopulmonary Dysplasia , 2013, The Journal of Immunology.

[75]  Karin Breuer,et al.  InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation , 2012, Nucleic Acids Res..

[76]  Greg W. Clark,et al.  Coevolution Reveals a Network of Human Proteins Originating with Multicellularity , 2012, Molecular biology and evolution.

[77]  M. Pino-Yanes,et al.  IL-1 receptor-associated kinase 3 gene (IRAK3) variants associate with asthma in a replication study in the Spanish population. , 2012, The Journal of allergy and clinical immunology.

[78]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[79]  L. Lu,et al.  The orphan disease networks. , 2011, American journal of human genetics.

[80]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[81]  Theo Stijnen,et al.  Random effects meta‐analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data , 2010, Statistics in medicine.

[82]  S. Yuan,et al.  Melatonin reduces acute lung injury in endotoxemic rats. , 2009, Chinese medical journal.

[83]  A. Hyman,et al.  Genome-scale RNAi profiling of cell division in human tissue culture cells , 2007, Nature Cell Biology.

[84]  D. Schlessinger,et al.  IRAK-M is involved in the pathogenesis of early-onset persistent asthma. , 2007, American journal of human genetics.

[85]  D. Aw,et al.  Immunosenescence: emerging challenges for an ageing population , 2007, Immunology.

[86]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[87]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[88]  Yusuke Nakamura,et al.  An association study of asthma and related phenotypes with polymorphisms in negative regulator molecules of the TLR signaling pathway , 2006, Journal of Human Genetics.

[89]  A. E. Hirsh,et al.  Adjusting for selection on synonymous sites in estimates of evolutionary distance. , 2005, Molecular biology and evolution.

[90]  Renji Reghunathan,et al.  Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome , 2005, BMC Immunology.

[91]  C. Perry,et al.  Cefdinir , 2012, Drugs.

[92]  P. Stenson,et al.  Human Gene Mutation Database (HGMD®): 2003 update , 2003, Human mutation.

[93]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[94]  L. Nogee.  Abnormal expression of surfactant protein C and lung disease. , 2002, American journal of respiratory cell and molecular biology.

[95]  H. Maeda,et al.  Nitric oxide and virus infection , 2000, Immunology.

[96]  M. Triggiani,et al.  Arachidonic acid metabolism in inflammatory cells of patients with bronchial asthma , 2000, Allergy.

[97]  A. Berger.  What are leukotrienes and how do they work in asthma? , 1999, BMJ.

[98]  S. Liggett,et al.  Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. , 1993, American journal of respiratory cell and molecular biology.

[99]  B. Samuelsson.  Arachidonic acid metabolism: role in inflammation. , 1991, Zeitschrift fur Rheumatologie.

[100]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[101]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.